InspireMD Announces the Appointment of Dan Dearen to its Board of Directors
InspireMD (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system, has appointed Dan Dearen to its Board of Directors. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors.
Dearen's notable achievements include serving as President, co-Founder, and CFO of Axonics, Inc., which was acquired by Boston Scientific for $3.7 billion in November 2024. He also held key positions at Vessix Vascular (acquired by Boston Scientific for $425 million) and currently serves on the boards of JenaValve Technology and BetaBionics.
This appointment comes at a strategic time as InspireMD continues its U.S. commercial launch of CGuard Prime, following FDA approval.
InspireMD (Nasdaq: NSPR), sviluppatore del sistema stent carotideo CGuard Prime, ha nominato Dan Dearen nel suo Consiglio di Amministrazione. Dearen porta con sé quasi 40 anni di esperienza dirigenziale nei settori dei dispositivi medici e delle scienze della vita.
Tra i suoi risultati degni di nota figurano i ruoli di Presidente, co-fondatore e CFO di Axonics, Inc., acquisita da Boston Scientific per 3,7 miliardi di dollari nel novembre 2024. Ha ricoperto anche posizioni chiave in Vessix Vascular (acquisita da Boston Scientific per 425 milioni di dollari) ed è attualmente membro dei consigli di JenaValve Technology e BetaBionics.
Questo incarico arriva in un momento strategico, poiché InspireMD prosegue il lancio commerciale negli Stati Uniti di CGuard Prime, dopo l'approvazione FDA.
InspireMD (Nasdaq: NSPR), desarrollador del sistema de stents carotídeos CGuard Prime, ha designado a Dan Dearen para su Junta Directiva. Dearen aporta casi 40 años de experiencia en puestos de liderazgo en los sectores de dispositivos médicos y ciencias de la vida.
Entre sus logros más destacados figuran haber sido Presidente, cofundador y CFO de Axonics, Inc., adquirida por Boston Scientific por 3,7 mil millones de dólares en noviembre de 2024. También ocupó puestos clave en Vessix Vascular (adquirida por Boston Scientific por 425 millones de dólares) y actualmente forma parte de los consejos de JenaValve Technology y BetaBionics.
Este nombramiento llega en un momento estratégico mientras InspireMD continúa su lanzamiento comercial en EE. UU. de CGuard Prime, tras la aprobación de la FDA.
InspireMD (Nasdaq: NSPR), CGuard Prime 경동맥 스텐트 시스템의 개발사,가 이사회에 Dan Dearen을 임명했습니다. Dearen은 의학기기 및 생명과학 분야에서 약 40년의 리더십 경력을 보유하고 있습니다.
그의 주목할 만한 업적으로는 Axonics, Inc.의 사장, 공동 창립자 및 CFO로 재직했고, 이 회사가 2024년 11월 Boston Scientific에 37억 달러에 인수된 점이 있습니다. 또한 Vessix Vascular에서 핵심 직책을 맡았으며 (Boston Scientific에 4.25억 달러에 인수), 현재 JenaValve Technology 및 BetaBionics 이사회에 재직 중입니다.
이번 임명은 InspireMD가 FDA 승인을 받은 후 미국 내 CGuard Prime의 상업 출시를 계속하는 전략적 시기에 이루어졌습니다.
InspireMD (Nasdaq: NSPR), développeur du système de stents carotidiens CGuard Prime, a nommé Dan Dearen au conseil d'administration. Dearen apporte près de 40 ans d'expérience en leadership dans les secteurs des dispositifs médicaux et des sciences de la vie.
Parmi ses réalisations notables figurent le poste de Président, co-fondateur et directeur financier d', qui a été rachetée par Boston Scientific pour 3,7 milliards de dollars en novembre 2024. Il a également occupé des postes clés chez Vessix Vascular (acquise par Boston Scientific pour 425 millions de dollars) et siège actuellement aux conseils d'administration de JenaValve Technology et BetaBionics.
Cette nomination intervient à un moment stratégique alors qu'InspireMD poursuit son lancement commercial américain de CGuard Prime, après l'approbation de la FDA.
InspireMD (Nasdaq: NSPR), Entwickler des CGuard Prime Carotis-Stent-Systems, hat Dan Dearen in den Vorstand berufen. Dearen bringt fast 40 Jahre Führungserfahrung in den Bereichen medizinische Geräte und Lebenswissenschaften mit.
Zu Dearens bemerkenswerten Leistungen gehört die Rolle als Präsident, Mitgründer und CFO von Axonics, Inc., das im November 2024 von Boston Scientific für 3,7 Milliarden Dollar übernommen wurde. Er hat auch Schlüsselpositionen bei Vessix Vascular bekleidet (von Boston Scientific für 425 Millionen Dollar übernommen) und sitzt derzeit in den Vorständen von JenaValve Technology und BetaBionics.
Diese Ernennung erfolgt zu einem strategischen Zeitpunkt, da InspireMD seinen US-Produktstart von CGuard Prime fortsetzt, nach der FDA-Zulassung.
InspireMD (Nasdaq: NSPR)، مطوّر نظام الدعامات السباتية CGuard Prime، عيّن دان ديران في مجلس إدارتها.
يَجلب Dearen حوالي 40 عامًا من الخبرة القيادية في قطاعات الأجهزة الطبية وعلوم الحياة.
من إنجازاته البارزة تولّيه منصب الرئيس، والمؤسس المشارك، والمدير المالي لشركة Axonics, Inc.، التي استحوذت عليها Boston Scientific مقابل 3.7 مليار دولار في نوفمبر 2024. كما شغل مناصب رئيسية في Vessix Vascular (المدرجة من قبل Boston Scientific مقابل 425 مليون دولار) ويخدم حالياً في مجالس إدارة JenaValve Technology وBetaBionics.
ويأتي هذا التعيين في وقت استراتيجي بينما تواصل InspireMD الإطلاق التجاري الأميركي لـ CGuard Prime عقب موافقة FDA.
InspireMD（纳斯达克股票代码：NSPR），CGuard Prime颈动脉支架系统的开发商，已任命 Dan Dearen 加入董事会。Dearen 具有近 40 年的领导经验，涵盖医疗设备和生命科学领域。
Dearen 的显著成就包括担任 Axonics, Inc. 的总裁、联合创始人及 CFO，该公司于 2024 年 11 月被 Boston Scientific 以 37 亿美元 收购。他还在 Vessix Vascular 担任要职（随后被 Boston Scientific 以 4.25 亿美元 收购），目前是 JenaValve Technology 和 BetaBionics 的董事会成员。
此次任命正值 InspireMD 在 FDA 批准后继续在美国推进 CGuard Prime 的商业化发行 的战略时期。
- Appointment of highly experienced medical device industry veteran with nearly 40 years of leadership experience
- New director has successful track record in leading companies to acquisitions (Axonics - $3.7B, Vessix - $425M)
- Strategic timing coincides with U.S. commercial launch of CGuard Prime following FDA approval
- Strengthens board expertise in financial and strategic planning during commercial expansion phase
- None.
MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution.
“We are pleased to welcome Dan to InspireMD’s Board of Directors,” said Marvin Slosman, Chief Executive Officer of InspireMD. “He brings extensive experience, financial expertise, and strategic insight to InspireMD as we advance on our mission to lead the carotid intervention market and execute our long-term value-creation strategy. His arrival is perfectly timed as we continue our U.S. commercial launch of CGuard Prime and advance our position in the market.”
“I look forward to working with Dan and the entire InspireMD Board as we continue to build our business and advance our growth,” said Paul Stuka, Chairman of the InspireMD Board of Directors. “Dan’s track record of execution and leadership experience make him an ideal addition to our Board, and we look forward to his contributions.”
“I am honored to join the Board of InspireMD at this pivotal time for the company. With FDA approval for the CGuard Prime stent system in hand, InspireMD has the potential to change the standard of care in vascular medicine and greatly improve the lives of patients,” said Mr. Dearen. “This is a remarkable time for the company, and I look forward to supporting the team through this vast opportunity for growth.”
Mr. Dearen previously served as President, co-Founder, and Chief Financial Officer of Axonics, Inc., During his tenure, Axonics went public and became one of the fastest-growing companies in the medical device sector, helping over 300,000 patients find relief from bladder and bowel dysfunction. Axonics, Inc. was acquired by Boston Scientific in November 2024 for
Until July 2024, Mr. Dearen also served as Chair of the Audit Committee and a Board member at Endotronix, a medical device company leveraging pulmonary artery (PA) pressure and vital sign data to improve care for patients with heart failure. He currently holds the same roles at JenaValve Technology, a developer of innovative transcatheter heart valve (THV) solutions, and BetaBionics (NASDAQ: BBNX), the creator of the iLet Bionic Pancreas, an autonomous insulin delivery system that determines every insulin dose for patients with diabetes. Prior to co-founding Axonics, Mr. Dearen held the role of Chief Operating and Financial Officer at Vessix Vascular, a medical device company focused on hypertension therapies, which Boston Scientific acquired in 2012 for
Mr. Dearen’s appointment to the Board of Directors follows the appointment of Mr. Ray Cohen, announced in July 2025.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including expectations regarding U.S. commercial launch and expansion. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; substantial doubt about our ability to continue as a going concern; significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ
Who is Dan Dearen and why did InspireMD (NSPR) appoint him to the Board?
What is InspireMD's (NSPR) main product and current business focus?
What are Dan Dearen's current board positions besides InspireMD (NSPR)?
What significant acquisitions has Dan Dearen been involved with?
How does Dan Dearen's appointment align with InspireMD's (NSPR) strategy?
